Spondyloarthritis & psoriatic arthritis
Anti-TNF-α induced paradoxical psoriasis in patients with ankylosing spondylitis: a systematic review
Authors' conclusion
PP is an uncommon adverse reaction to TNFi treatment in AS patients and responds well to drug withdrawal.
Study context
- Population
- Ankylosing spondylitis (AS) patients treated with TNFi
- Outcome
- Characteristics and frequency of paradoxical psoriasis (PP) in AS patients treated with different TNFi
Methodological detailsPRISMA guidelines, MEDLINE via Pubmed and Cochrane library, inception to January 2023
- PRISMA guidelines
- MEDLINE via Pubmed and Cochrane library, inception to January 2023
Pooled result
As reported in the abstract
Paradoxical psoriasis in TNFi-treated AS patients
Frequency of paradoxical psoriasis (PP)
0.5-1%
Latency period
2-11 months
Original publication
Anti-TNF-α induced paradoxical psoriasis in patients with ankylosing spondylitis: a systematic review. Clin Exp Rheumatol. Published 2 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →